These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26380154)

  • 1. Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers.
    van Rongen A; Kervezee L; Brill M; van Meir H; den Hartigh J; Guchelaar HJ; Meijer JH; Burggraaf J; van Oosterhout F
    CPT Pharmacometrics Syst Pharmacol; 2015 Aug; 4(8):454-64. PubMed ID: 26380154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
    Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
    Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam.
    Tomalik-Scharte D; Suleiman AA; Frechen S; Kraus D; Kerkweg U; Rokitta D; Di Gion P; Queckenberg C; Fuhr U
    J Clin Pharmacol; 2014 Oct; 54(10):1162-9. PubMed ID: 24782075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
    Li X; Junge L; Taubert M; von Georg A; Dahlinger D; Starke C; Frechen S; Stelzer C; Kinzig M; Sörgel F; Jaehde U; Töx U; Goeser T; Fuhr U
    J Clin Pharmacol; 2020 Sep; 60(9):1237-1253. PubMed ID: 32427354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam.
    Shord SS; Chan LN; Camp JR; Vasquez EM; Jeong HY; Molokie RE; Baum CL; Xie H
    Br J Clin Pharmacol; 2010 Feb; 69(2):160-6. PubMed ID: 20233179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraindividual Variability in Absolute Bioavailability and Clearance of Midazolam in Healthy Individuals.
    Kvitne KE; Drevland OM; Haugli N; Skadberg E; Zaré HK; Åsberg A; Robertsen I
    Clin Pharmacokinet; 2023 Jul; 62(7):981-987. PubMed ID: 37162619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach.
    Brussee JM; Yu H; Krekels EHJ; Palić S; Brill MJE; Barrett JS; Rostami-Hodjegan A; de Wildt SN; Knibbe CAJ
    Pharm Res; 2018 Jul; 35(9):182. PubMed ID: 30062590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.
    Knoester PD; Jonker DM; Van Der Hoeven RT; Vermeij TA; Edelbroek PM; Brekelmans GJ; de Haan GJ
    Br J Clin Pharmacol; 2002 May; 53(5):501-7. PubMed ID: 11994056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex differences in CYP3A activity using intravenous and oral midazolam.
    Chen M; Ma L; Drusano GL; Bertino JS; Nafziger AN
    Clin Pharmacol Ther; 2006 Nov; 80(5):531-8. PubMed ID: 17112809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study.
    van Groen BD; Krekels EHJ; Mooij MG; van Duijn E; Vaes WHJ; Windhorst AD; van Rosmalen J; Hartman SJF; Hendrikse NH; Koch BCP; Allegaert K; Tibboel D; Knibbe CAJ; de Wildt SN
    Clin Pharmacol Ther; 2021 Jan; 109(1):140-149. PubMed ID: 32403162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
    Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion.
    Nassar YM; Hohmann N; Michelet R; Gottwalt K; Meid AD; Burhenne J; Huisinga W; Haefeli WE; Mikus G; Kloft C
    Clin Pharmacokinet; 2022 Nov; 61(11):1595-1607. PubMed ID: 36195807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics.
    Lau CE; Ma F; Wang Y; Smith C
    Psychopharmacology (Berl); 1996 Aug; 126(3):241-8. PubMed ID: 8876024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
    Padhi D; Salfi M; Emery M
    Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
    Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
    Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects.
    Wong SL; Goldberg MR; Ballow CH; Kitt MM; Barriere SL
    Pharmacotherapy; 2010 Feb; 30(2):136-43. PubMed ID: 20099988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic analysis of diurnal and seasonal variations of plasma concentrations of cilostazol in healthy volunteers.
    Lee D; Son H; Lim LA; Park K
    Ther Drug Monit; 2014 Dec; 36(6):771-80. PubMed ID: 24739664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.